Pilot Study to Evaluate Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (Clinical and Sub-clinical), When Treated With Aldara 5% (Imiquimod) Cream

NCT00294320 Phase 3 COMPLETED

The purpose of this study is to evaluate the performance of two techniques to monitor the clearance of AK lesions when treated with Aldara 5% cream.

Details

Lead sponsor	MEDA Pharma GmbH & Co. KG
Phase	Phase 3
Status	COMPLETED
Enrolment	12
Start date	2006-02
Completion	2007-01

Conditions

• Actinic Keratosis

Interventions

• Aldara (Imiquimod)
• Vehicle cream

Primary outcomes

• To compare the performance of two techniques to monitor the clearance of AK lesions (clinical and subclinical) when treated with Aldara 5% cream by comparison of lesion counts. — 8 weeks after the end of treatment

Countries

France